Valuation: Carmat SA

Market Cap 6.15M 6.8M 5.67M 5.13M 9.69M 639M 9.98M 68.09M 27.06M 342M 25.51M 24.96M 1.09B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 65.52M 54.69M 49.5M 93.41M 6.16B 96.21M 656M 261M 3.29B 246M 241M 10.48B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.09900000
0.1
1 year 0.1
Extreme 0.09900000
0.1
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
27.55
10 years 0.08
Extreme 0.085
36.93
Manager TitleAgeSince
Chief Executive Officer 55 2016-08-31
Director of Finance/CFO - 2018-12-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 2017-01-01
Director/Board Member 79 2017-04-19
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Sell

Chairman

1,343,333 2.3347%
3/13/25 Buy

Chairman

1,343,333 2.3347%
5/29/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-97.86% 7.08M
-1.87%-5.59%-16.74%+14.13% 186B
-0.61%-3.67%+5.41%+42.88% 124B
-2.01%-6.77%-14.96%+14.17% 119B
+0.86%-6.40%-43.29%+2.63% 91.43B
-0.14%+2.86%-3.86%+76.84% 66.67B
+0.55%+1.01%+12.28%-8.07% 58.76B
-0.65%+4.07%-2.18%+62.81% 54.99B
-0.68%+6.83%-1.64%+55.26% 49.93B
-5.17%+0.55% - - 35.13B
Average -0.97%-1.78%-7.22%+18.09% 79B
Weighted average by Cap. -1.03%-3.37%-10.56%+27.61%

Financials

2023 2024
Net sales 3.84M 4.24M 3.54M 3.21M 6.05M 399M 6.23M 42.51M 16.89M 213M 15.92M 15.59M 679M 7.34M 8.12M 6.78M 6.14M 11.58M 763M 11.93M 81.37M 32.34M 408M 30.48M 29.83M 1.3B
Net income -53.87M -59.57M -49.72M -45.01M -84.93M -5.6B -87.48M -597M -237M -2.99B -224M -219M -9.53B -51.4M -56.83M -47.44M -42.94M -81.03M -5.34B -83.46M -569M -226M -2.86B -213M -209M -9.09B
Net Debt 49.64M 54.89M 45.82M 41.47M 78.26M 5.16B 80.6M 550M 219M 2.76B 206M 202M 8.78B 53.1M 58.72M 49.01M 44.37M 83.72M 5.52B 86.23M 588M 234M 2.95B 220M 216M 9.39B
Projected Income Statement - Annual - Carmat SA
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock